Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA granted Opdivo an ultra-rapid approval for the treatment of classical Hodgkin lymphoma that has relapsed or progressed, making it the first PD-1 inhibitor approved for hematological cancer.


Related Content

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
One Down, Two To Go For Adcetris’ Expansion In Lymphoma
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst